Cannabidiol - TALENT Biotech

Drug Profile

Cannabidiol - TALENT Biotech

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator TALENT Biotech
  • Class Analgesics; Antiepileptic drugs; Antipsychotics; Anxiolytics; Cannabinoids; Muscle relaxants; Neuroprotectants; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Serotonin 1 receptor agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II Graft-versus-host disease

Most Recent Events

  • 24 Jan 2017 Preclinical trials in Graft-versus-host disease in Israel (unspecified route)
  • 24 Jan 2017 Talent Biotech completes a phase II trial in Graft versus Host Disease in Israel before January 2017
  • 18 Jan 2017 Phase-II clinical trials in Graft-versus-host disease (Prevention) in Israel (PO) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top